Drug intelligence / Profile preview

CB48

Development stage: Preclinical
Lead developer: Cartography Biosciences
Modality: Antibody-Based Therapeutics

Overview

CB48 is an experimental antibody drug developed by Cartography Biosciences. It is referenced as part of a bispecific antibody combination, CB34×CB48, which is in the discovery phase for the treatment of neoplasms, specifically solid tumors. The precise mechanism of action and molecular targets for CB48 have not been disclosed publicly as of June 2025. The drug has not yet entered clinical trials and remains in preclinical research stages[1][3].

Beyond the preview

Go deeper on CB48.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB48.

Explore the full profile